Deep Genomics

Deep Genomics is a biotechnology company focused on developing RNA therapies for any gene and genetic condition. The company’s proprietary AI Platform untangles the complexity in RNA biology, identifies novel targets, and evaluates thousands of possibilities to identify the best therapeutic candidates. Designed for data-driven prediction, positive feedback loops, and exponential growth, the AI Platform unlocked its first targets in 2018, addressing RNA splicing defects and correction mechanisms. In 2023, Deep Genomics released BigRNA, the first Foundation Model for RNA Biology, which can discover new biological mechanisms and RNA therapeutic candidates that traditional approaches might miss. BigRNA is trained to predict RNA expression at sub-gene resolution and performs tasks such as target identification, discovering novel biological mechanisms, predicting molecule-target interactions, and designing therapeutic candidates across various species, tissues, cell models, and RNA therapeutic modalities. Deep Genomics is currently developing BigRNA+ to expand the number of mechanisms and genetic variants they can pursue. The company raised $180M in Series C financing in July 2021. Deep Genomics has offices in Toronto and Boston, with its AI platform and preclinical research teams based in Toronto, and its clinical development and business development teams led out of Boston. The Toronto lab and office are located in and around the MaRS tower, near the University of Toronto, four research hospitals, three medical research institutes, and the AI research labs of Google, Uber, and the Vector Institute for Artificial Intelligence.